BEGIN:VCALENDAR
VERSION:2.0
PRODID:Spatie calendar-links
BEGIN:VEVENT
UID:8fa93240d21e3bd822fec1e6da190cb7
SUMMARY:Visual Abstracts Thursday\n\n
DTSTAMP:20240912T133000Z
DTSTART:20240912T133000Z
DTEND:20240912T140000Z
DESCRIPTION:Visual Abstracts Thursday\n\n\n\nPresentations:\n\nMaintenance of spike-specific CD8 T cells after SARS-CoV-2 mRNA vaccination in anti-CD20 treated patients\nReferent(s): N. Heikkila\, Geneva (CH)\; N. Madelon\, Genève (CH)\; P. Fontannaz\, Geneva (CH)\; W. Adouan\, Geneva (CH)\; G. Breville\, Geneve (CH)\; K. Lauper\, Geneve (CH)\; R. Goldstein\, Geneva (CH)\; A. Grifoni\, San Diego (CH)\; A. Sette\, Geneve (CH)\; C. A. Siegrist\, Geneve (CH)\; A. Finkch\, Geneve (CH)\; P. Lalive\, Geneve (CH)\; R. Genolet\, Lausanne (CH)\; A. Didierlaurent\, Genève (CH)\; C. Eberhardt\, Genève (CH)\n\nPerformance of a novel\, fully automated immunoassay microarray prototype for the serological detection of specific IgE directed against Bet v 1\nReferent(s): G. Gomez\, Eysins (CH)\; Y. Ataman-Önal\, Eysins (CH)\; B. Steele\, Edinburgh (GB)\; R. Pasion-Galvan\, Eysins (CH)\; J. Santiago\, Chicago (US)\; M. Hausmann\, Eysins (CH)\; C. Fischer\, Eysins (CH)\n\nExploring cross-reactive T cell immunity in Guillain-Barr&eacute\; syndrome\nReferent(s): C. Capelle\, Zurich (CH)\; L. Súkeníková\, Zurich (CH)\; D. Latorre\, Zurich (CH)\; P. Piffaretti\, Zurich (CH)\; S. Edalat\, Zurich (CH)\; B. Schreiner\, Zurich (CH)\; P. Ripellino\, Lugano (CH)\n\nT-safe: a tolerogenic niche for T-reg priming to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation.\nReferent(s): N. Kallal\, GENEVE (CH)\; S. Hugues\, Genève (CH)\; F. Bonini\, Geneve (CH)\; F. Simonetta\, GENEVE (CH)\; F. Fico\, Geneve (CH)\; C. Bernardi\, GENEVE (CH)\n\nIgG-Epitope Mapping of Birch-Pollen Bet v 1 Allergen in Allergic and Treated Patients for the Design of Hypoallergenic Immunotherapy Allergens\nReferent(s): M. Paolucci\, Zurich (CH)\; D. Melillo\, Zutrich (CH)\; C. Lang\, Zürich (CH)\; A. Duda\, Zurich (CH)\; M. Bachmann\, Bern (CH)\; P. Johansen\, Zurich (CH)\; L. Šošić\, Zurich (CH)\; A. Streuli\, Zurich (CH)\; G. Sousa-Augusto\, Bern (CH)\; T. Jiang\, Vienna (AT)\; R. Campana\, Vienna (AT)\; P. Schmid-Grendelmeier\, Zurich (CH)\; K. Eyer\, Zurich (CH)\; T. M. Kündig\, Zurich (CH)\n\nInnate immune cell dysregulation in children with periodic fever\, aphthous stomatitis\, pharyngitis\, adenitis (PFAPA)\nReferent(s): A. Dernstedt\, Geneva (CH)\; G. Blanchard-Rohner\, Geneva (CH)\; P. Girard\, Geneva (CH)\; E. Sallansonnet\, Geneva (CH)\; E. Arsac\, Geneva (CH)\; P. Fontannaz\, Geneva (CH)\; S. Lemeille\, Geneva (CH)\; A. Didierlaurent\, Genève (CH)\n\nCharacterization of anti-IgE molecules to inhibit IgE:receptor interactions and suppress IgE production in B-cells.\nReferent(s): P. Guntern\, Bern (CH)\; L. Pennington\, Stanford (US)\; S. Nyffeler\, Bern (CH)\; T. Jardetzky\, Stanford (US)\; A. Eggel\, Bern (CH)\n\nElevated serum levels of IL-18 discriminate Still&rsquo\;s Disease from other autoinflammatory conditions: results from a unique European cohort\nReferent(s): C. Girard-Guyonvarc'h\, Genève (CH)\; E. Rodriguez\, Genève (CH)\; A. Caruso\, Genève (CH)\; C. Gabay\, Genève (CH)\n\nFine tuning CD19-CAR sensitivity by modulating the CD28 transmembrane and intracellular domains\nReferent(s): O. Alfageme-Abelló\, Lausanne (CH)\; E. Lana\, Lausanne (CH)\; R. Porret\, Lausanne (CH)\; L. Ermellino\, Lausanne (CH)\; A. Alcaraz-Serna\, Lausanne (CH)\; S. Georgakis\, Lausanne (CH)\; C. Petrovas\, Lausanne (CH)\; L. Perez\, Lausanne (CH)\; R. Cecchin\, Lausanne (CH)\; Y. Muller\, Lausanne (CH)\; P. Nunes-Hasler\, Geneva (CH)\n\nMechanistic evaluation of JAK inhibitor-mediated impairment of vaccine response in mouse models.\nReferent(s): P. Torres Rodríguez\, Geneva (CH)\; N. Madelon\, Genève (CH)\; Y. Donati\, Genève (CH)\; G. Ruiz Buendia\, Genève (CH)\; P. Fontannaz\, Geneva (CH)\; A. Didierlaurent\, Genève (CH)\n\nHLA-E protects genetically engineered porcine endothelial cells from the lysis of natural killer cells in 2D and 3D microfluidic systems.\nReferent(s): T. Tran\, Geneva (CH)\; V. Galdina\, Geneva (CH)\; O. Urquidi Gandarillas\, Geneva (CH)\; R. Rieben\, Bern (CH)\; E. Wolf\, Munich (DE)\; E. Kemter\, Munich (DE)\; G. Puga Yung\, Geneva (CH)\; J. Seebach\, Genève (CH)\; T. Adachi\, Geneva (CH)\n\nIs NLRC5\, a transcriptional regulator of MHCI genes\, controlled by the same conformational changes of inflammasome-forming NLRs?\nReferent(s): J. Guerra\, Bellinzona (CH)\; L. Varani\, Bellinzona (CH)\; R. Thakur\, Bellinzona (CH)\; A. Zenobi\, Bellinzona (CH)\; P. Cejka\, Bellinzona (CH)\; D. Morone\, Bellinzona (CH)\; L. Simonelli\, Bellinzona (CH)\; G. Guarda\, Bellinzona (CH)\n\nWhy do NK-92 cells lack the surface expression of CD16A?\nReferent(s): M. Andreani\, Geneva (CH)\; M. Freitas Monteiro\, Geneva (CH)\; A. Réal\, Geneva (CH)\; G. Puga Yung\, Geneva (CH)\; J. Seebach\, Genève (CH)\n\nXenotransplantation: Innovative approaches for functional assessment of human anti-pig cytotoxic T cells in vitro\nReferent(s): V. Galdina\, Geneva (CH)\; T. Tran\, Geneva (CH)\; R. Rieben\, Bern (CH)\; E. Wolf\, Munich (DE)\; E. Kemter\, Munich (DE)\; G. Puga Yung\, Geneva (CH)\; J. Seebach\, Genève (CH)\n\nTLR7-9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity.\nReferent(s): M. Rebsamen\, Epalinges (CH)\; A. Drobek\, Epalinges (CH)\; L. Bernaleau\, Epalinges (CH)\; M. Delacrétaz\, Epalines (CH)\; S. Calderon Copete\, Lausanne (CH)\; J. Korzeniowski\, Epalinges (CH)\; M. Monguio Tortajada\, Epalinges (CH)\; M. Longepierre\, Epalinges (CH)\; J. Marquis\, Lausanne (CH)\n\nHow nociceptors shape the tumor microenvironment in melanoma and breast cancer\nReferent(s): L. Garnier\, Geneva (CH)\; M. Madec\, Geneva (CH)\; L. Basso\, Toulouse (FR)\; S. Hugues\, Genève (CH)\n\nDoes c-MYC modulate metabolism and effector functions in TLR activated B cells?\nReferent(s): M. Pezzoli\, Basel (CH)\; R. Steiner\, Basel (CH)\; G. Bantug\, Basel (CH)\; C. Hess\, Basel (CH)\n\nSHAECS: The Swiss Hereditary Angioedema Cohort Study\nReferent(s): I. Morales\, Bern (CH)\; C. Weber\, Zurich (CH)\; W. A. Wuillemin\, Lucerne (CH)\; S. Zeerleder\, Lucerne (CH)\; B. Lucas\, Zürich (CH)\; K. Hartmann\, Basel (CH)\; M. Fontana\, Mendrisio (CH)\; P. Jandus\, Geneva (CH)\; L. Arlettaz\, Sion (CH)\; L. Jörg\, Bern (CH)\; C. Ribi\, Lausanne (CH)\; B. Ballmer-Weber\, St.Gallen (CH)\; A. Neff\, St.Gallen (CH)\; H. Hengartner\, St.Gallen (CH)\; U. C. Steiner\, Bern (CH)\n\nA helminth enzyme subverts macrophage-mediated immunity by epigenetic targeting of prostaglandin synthesis\nReferent(s): S. Bohnacker\, Epalinges (CH)\; F. D. Henkel\, Munich (DE)\; F. Hartung\, Munich (DE)\; A. Geerlof\, Neuherberg (DE)\; S. Riemer\, Munich (DE)\; U. F. Prodjinotho\, Munich (DE)\; E. Ben Salah\, Epalinges (CH)\; A. Santos Dias Mourão\, Neuherberg (DE)\; S. Bohn\, Martinsried (DE)\; T. Teder\, Stockholm (SE)\; D. Thomas\, Frankfurt (DE)\; R. Gurke\, Frankfurt (DE)\; C. Boeckel\, Neuherberg (DE)\; M. Ud-Dean\, Neuherberg (DE)\; A. C. König\, Neuherberg (DE)\; A. Quaranta\, Stockholm (SE)\; F. Alessandrini\, Munich (DE)\; A. Lechner\, Munich (DE)\; B. Spitzlberger\, Munich (DE)\; A. M. Kabat\, Freiburg (DE)\; E. Pearce\, Freiburg (DE)\; J. Z. Haeggström\, Stockholm (SE)\; S. M. Hauck\, Neuherberg (DE)\; C. E. Wheelock\, Stockholm (SE)\; P. J. Jakobsson\, Stockholm (SE)\; M. Sattler\, Neuherberg (DE)\; D. Voehringer\, Erlangen-Nürnberg (DE)\; M. J. Feige\, Garching (DE)\; C. Prazeres Da Costa\, Munich (DE)\; J. Esser-Von-Bieren\, Lausanne (CH)\n\nInvestigation of the role of IL-33 for intestinal tumorigenesis\nReferent(s): A. Herbst\, Bern (CH)\; V. Vu\, Bern (CH)\; M. H. Wasmer\, Bern (CH)\; S. J. Eugster\, Bern (CH)\; P. Krebs\, Bern (CH)\; A. Chatziioannou\, Athens (GR)\; E. Pilalis\, Athens (GR)\n\nAssociation of cytokines with Myasthenia Gravis in Algerian patients\nReferent(s): R. Raache\, Algiers (DZ)\; N. M. Bouchtout\, Alger (DZ)\; E. Attal\, Alger (DZ)\; C. Touil-Boukoffa\, Alger (DZ)\; N. Attal\, Alger (DZ)\n\nMatrix metalloproteinase and oxidative stress in systemic lupus erythematosus\nReferent(s): S. Louahchi\, Algiers (DZ)\; R. Raache\, Algiers (DZ)\; N. Khaldoun\, Algiers (DZ)\; A. Galleze\, Algiers (DZ)\; F. Hanni\, Algiers (DZ)\; C. Touil-Boukoffa\, Algiers (DZ)\n\nAcute and chronic myocardial inflammatory disease - the explorative prospective ImmpathCarditis study\nReferent(s): E. S. Payne\, Zurich (CH)\; A. Joachimbauer\, Zurich (CH)\; N. A. Cadosch\, St. Gallen (CH)\; C. Gil Cruz\, St. Gallen (CH)\; C. Perez-Shibayama\, St. Gallen (CH)\; K. Frischmann\, St. Gallen (CH)\; F. Tanner\, Zurich (CH)\; F. Ruschitzka\, Zurich (CH)\; B. Ludewig\, Zurich (CH)\; D. Schmidt\, Zurich (CH)\n\nInvestigation of the detailed mechanisms of skin barrier dysfunction and inflammation caused by surfactants\nReferent(s): M. Li\, Davos (CH)\; P. D’avino\, Davos (CH)\; H. Babayev\, Davos (CH)\; D. Yazici\, Davos (CH)\; P. Gessner\, Davos (CH)\; P. Westermann\, Davos (CH)\; N. Gaudenzio\, Toulouse (FR)\; C. Messner\, Davos (CH)\; S. Simmons\, Los Angeles (US)\; A. Almada\, Los Angeles (US)\; C. Akdis\, Davos Wolfgang (CH)\; Y. Mitamura\, Davos (CH)\n\nIntranodal injection of Immune Activator demonstrates antitumor efficacy in an adjuvant approach\nReferent(s): M. Mohsen\, Bern (CH)\; R. Josi\, Bern (CH)\; A. Sole\, Bern (CH)\; A. Ogrina\, Riga (LV)\; I. Balke\, Riga (LV)\; S. de Brot\, Bern (CH)\n\n
END:VEVENT
END:VCALENDAR